(What’s Left of) Our Economy: A Fed Snapshot of U.S. Manufacturing at the CCP Virus Turning Point?

Tags

737 Max, aircraft, aircraft parts, aluminum, Boeing, capital goods, CCP Virus, China, coronavirus, COVID 19, Federal Reserve, industrial production, Joe Biden, machinery, manufacturing, medical devices, metals, pharmaceuticals, PPE, safety, steel, tariffs, Trump, Wuhan virus, {What's Left of) Our Economy

If the Federal Reserve’s monthly industrial production report for February (released in March) was the last such data set assessing domestic U.S. manufacturing’s health before the full force of the CCP Virus pandemic struck the American economy, today’s release (covering November) might be viewed in retrospect as marking the close of the industry’s virus-induced slump – or at least the beginning of the end.

Clearly, the entire U.S. economy remains far from fully recovered from the pandemic and the shutdowns and lockdowns and behavioral changes it produced. Moreover, the virus’ second wave could well prompt renewed restrictions – though lockdown fatigue will probably keep them more limited than their springtime predecessors.

But shortly after the Fed compiled the figures for November came two developments capable of boosting domestic manufacturing output considerably – Washington’s certification clearing Boeing’s troubled 737 Max model jetliner for flight once again, and the announcements that large-scale final-phase clinical trials for two anti-CCP Virus vaccines revealed amazing efficacy rates and reassuring safety results.

At the same time, these last pre-737 and vaccine manufacturing production numbers showed once again how relatively well domestic industry has held up during the CCP Virus period so far, and how strong its post-April recovery has been. By the same token, the data once more make clear the benefits of the Trump administration’s sweeping tariffs on products from China and its levies on steel and aluminum imports – which sharply limited the extent to which U.S. demand for these goods could be met from abroad.

The 0.79 percent November monthly increase in after-inflation manufacturing output recorded by the Fed was weaker than the October figure. But that month’s increases was revised up from a strong 1.04 percent to an even better 1.19 percent. September’s previously reported fractional increase remained basically the same.

As of November, therefore, real manufacturing production has improved by 20.67 percent above its April pandemic-induced trough and, just as important, stands just 3.50 percent lower than its final pre-CCP Virus level in February.

The November numbers are also notable for the outsized role played once again by the automotive sector. Although its October sequential inflation-adjusted output performance has been revised from a virtual “no change” to a 1.14 percent drop, these first November results show a 5.32 percent surge. More important than this volatility, though, is that combined vehicle and parts output is now just 0.38 percent lower than its final pre-pandemic level in February.

One indication of at least short-term concern from the November results: Constant-dollar production in the big machinery sector slipped by 0.51 percent on month. This industry matters greatly because its products are used so widely throughout the economy (e.g., construction, agriculture), and because it contains the capital goods products on which manufacturers themselves rely so heavily to turn out their own goods.

Longer term, the machinery picture looks better, though, as in line with the generally strong capital investment data kept by Washington, its price-adjusted output is now off by just 3.52 percent since February.

As for the tariff angle mentioned above, its importance is evident not simply from the strong overall manufacturing recovery, but from the performance of the primary metals sector, whose performance since March, 2018 has been profoundly affected by levies on steel and aluminum from most major exporting countries.

Constant dollar output of primary metals plunged by 25.46 percent during the peak pandemic months of March and April – a rate faster than that of manufacturing’s total 20.03 percent. Since then, however, its grown in real terms by 25.63 percent (faster than manufacturing’s total 20.67 percent advance).

November, moreover, was no exception, as primary metals’ inflation-adjusted production rose by a robust 3.75 percent. These numbers might give apparent President-elect Joe Biden pause if he’s thinking of lifting the steel and aluminum levies as part of his announced goal of repairing U.S. alliance relations he believes have been gravely damaged by President Trump.

If the beginning of the end of pandemic really is at hand, the November Fed figures show that it can’t come soon enough for the nation’s beleaguered aircraft industry as well as for its pharmaceutical sector. The latter’s after-inflation output remained steady last month, but the levels themselves remained remarkably subdued. November’s 0.76 percent monthly constant dollar production decline followed a downwardly revised 1.01 percent October decrease, and year-on-year, inflation-adjusted output is off by 2.37 percent.

Despite Boeing- and travel-related woes, the aerospace industry has fared considerably better. After a real output nosedive of 32.85 percent in February and March, such production is up by a spectacular 47.75 percent since. And thanks partly to the 2.07 percent on-month improvement in November, real output is down just 3.77 percent since the last pre-pandemic figure in February.

Nonetheless, the 737 Max news and any sign a significant air travel comeback will be welcome for civilian aircraft and parts makers, as after-inflation production is still 15.40 percent less than it was last November.

But despite the number of inspiring anecdotal accounts of medical equipment and supplies manufacturers boosting production of face masks, protective gowns, ventilators, and the like in response to the medical emergency, overall real production of these vital products remained uninspiring in November. Real output rose on-month by 1.56 percent, but the October’s initially reported 3.54 percent after-inflation sequential production increase has now been downgraded to 2.04 percent.

Since April, moreover, the price-adjusted production rebound has been a mere 21.75 percent – not much stronger than that for the total manufacturing recovery. Perhaps most discouraging: Real output in this sector is actually down 5.60 percent – from levels revealed by major continuing reliance on imports to have been dangerously inadequate.

(What’s Left of) Our Economy: U.S. Manufacturing Output Held its Own in October

Tags

automotive, Boeing, CCP Virus, civilian aircraft, coronavirus, COVID 19, durable goods, Federal Reserve, industrial production, manufacturing, masks, medical devices, non-durable goods, pharmaceuticals, PPE, vaccines, Wuhan virus, {What's Left of) Our Economy

This morning’s monthly Federal Reserve industrial production report is an object lesson in not counting your real manufacturing output chickens too soon – that is, before the revisions hatch.

So keeping in mind that today’s data will be revised further several times as well, it looks like my concerns last month about manufacturing turning from a CCP Virus-era economic leader into a laggard might have been premature.

Not that today’s release, which brings the story through October, showed gangbuster results. Inflation-adjusted manufacturing output increased by 1.04 percent over September’s levels. Much more encouraging, though, were the continually positive overall revisions and especially those for September. Its initially reported 0.29 percent constant dollar monthly output decline is now reported as a fractional (0.01 percent) increase.

As a result, after having sunk by just over twenty percent from February (the last month before the virus began seriously weakening the economy’s performance) through its April bottom, after-inflation manufacturing production is up by 19.35 percent. Alternatively put, it’s 4.56 percent below the February level, and 3,61 percent lower than last October’s.

Today’s October release also provided more evidence that the automotive sector’s dominant role role in determining overall manufacturing growth has just about faded away. Combined vehicles and parts production remained virtually flat in October, after falling an upwardly revised 3.02 percent sequentially in September.

In addition, October’s figures confirmed that, within manufacturing, the non-durable goods supersector has outperformed its durable goods counterpart – mainly because its first-wave pandemic dropoff was so much less dramatic.

Between February and April, price-adjusted durable goods output (including automotive and the troubled aerospace sector – due to Boeing’s woes and the virus-related travel shutdown) plunged by 27.99 percent, versus a 11.53 percent decline in non-durables (which contains industries like food, healthcare goods, and paper products manufacturing).

Since April real durables output has rebounded by 31.22 percent. But it’s still 5.51 percent lower than in February, and 4.19 percent lower than last October.

Since April, non-durables’ real output is up by 9.06 percent. But since its decline was so much less severe than durables’, in after-inflation terms its production is just 3.51 percent off the February level, and 2.97 percent below last October’s figure.

And what of some of the obvious drivers – for good or ill – of manufacturing output during this CCP Virus era?

Between February and April, aircraft and parts production plunged by 32.85 percent. An astonishing 43.31 percent recovery since has left the sector only 3.77 percent production-wise than in February. But because Boeing’s woes predated the pandemic, this output remains down 17.79 percent year-on-year.

Oddly, constant dollar production of medical equipment and supplies (a category including face masks, protective gowns, and ventilators) dropped by 19.75 percent as the CCP Virus was surging between February and April. And since then, it’s risen only 23.20 percent – including an encouraging 3.54 percent monthly improvement in October. Year-on-year, moreover, these sectors have seen 2.73 percent real output growth, but that improvement suggests how modest – and in retrospect, how inadequate – production was before the pandemic.

Finally, pharmaceutical and medicines production has been steady all year long in inflation-adjusted terms, and advanced by a modest 0.12 percent sequentially in October. Year-on-year, moreover, output has grown by just 0.39 percent – which makes these industries of special interest in the months ahead as mass production of recent promising vaccines ramps up.

For now, though, overall, domestic manufacturing production more than held its own in October. But except for that vaccine production, as the virus second wave strengthens, its near-term future could be just as challenging as that of the rest of the economy and nation

(What’s Left of) Our Economy: Through the Pandemic Fog, Signs of Trump Trade Progress Keep Coming

Tags

(What's Left of) Our Economy, aircraft, Boeing, CCP Virus, Census Bureau, China, coronavirus, COVID 19, exports, goods trade, healthcare goods, imports, Made in Washington trade deficit, manufacturing, manufacturing trade deficit, medical devices, non-oil goods trade deficit, pharmaceuticals, services trade, tariffs, Trade, trade deficit, trade war, Trump, Wuhan virus

Proof positive that much of the U.S. government grinds on whatever the political tumult surrounding it: Despite the controversies that erupted due to the largely unexpected, still-incomplete, and increasingly contested Presidential election results, the Census Bureau nonetheless still put out the new monthly U.S. trade report yesterday – this one taking the story through September.

And by the bizarro economic standards of the bizarro CCP Virus era, the figures were strangely normal: The various September deficits remained awfully high given an economy whose levels are still markedly subdued despite a powerful growth rebound in the third quarter (which ended in September). Yet although these results have been widely interpreted as a stinging rebuke to effectiveness of President Trump’s tariff-centric trade policies (see, e.g., here and here), widely overlooked details reveal major mitigating developments – and resulting reasons for continued encouragement.

As for the awfully high deficits: The combined goods and services trade gap actually decreased on month by 4.73 percent, from a downwardly adjusted $67.04 billion to $63.86 billion. Yet this monthly total (during a troubled economic time) was still firmly in the neighborhood of trade shortfalls during the bubbly mid-2000s, when Washington’s trade policy was about as cluelessly import- and especially China-friendly as possible.

Moreover, back in those days, oil made up a much bigger share of the total goods deficit than today. So obviously, most of the remaining gap owes a good deal to U.S. trade policy decisions – as will be seen below.

Encouragingly, total U.S. exports to a world still largely struggling with virus-related downturns of its own were up 2.55 percent sequentially in September, and registered their best performance ($176.35 billion) since March – just as major pandemic effects were taking hold. Total September imports of $240.22 billion also represented the highest amount ($240.22 billion) since March, but the monthly increase was only 0.51 percent. And where export growth has consistently been strong since May, import growth has begun slowing markedly.

Yet the persistence of high combined goods and services U.S. trade shortfalls stems mainly from problems with services trade that are clearly CCP Virus-related. For example, the longstanding services surplus (which of course includes travel services) is on track for its biggest drop since recessionary 2001. So far, through the first three quarters of 2020, it’s sunk by 20.47 percent on a year-to-date basis.

Indeed, the $43.96 billion reduction in the services surplus has been greater than the $38.54 billion increase in the overall deficit – meaning that if the service surplus had simply remained the same, the total deficit would have declined year-to-date (although still less than expected at least during a normal deep recession).

As indicated above, however, the total trade numbers don’t tell the whole story about the successes or failures of trade policy. That’s because, as known by RealityChek regulars, services are one huge sector where trade agreements and similar decisions have had relatively little impact so far. Ditto for oil

At first glance, examing trade flows that are substantially “Made in Washington” also reveals a nice-sized monthly September reduction in that deficit (4.62 percent), but to a level that’s the third worst on record ($80.74 billion) – just behind the August and July totals, respectively. And on a year-to-date basis, the Made in Washington deficit is up 3.80 percent from last year,to $663.55 billion.

Yet here’s where another detail comes in. This entails the woes of Boeing, which have spread beyond the safety debacle stemming from crashes of its popular 737 Max model to the global virus-induced collapse in air travel.

The safety problems of 2019 cut the longstanding U.S. civilian aircraft trade surplus by nearly 28 percent, or $8.86 billion on a January-September basis. Had the surplus stayed stable, it would have risen only from $600.08 billion during the first three quarters of 2018 to $630.39 billion, rather than $639.25 billion. Given all the import front-running seen throughout 2019 to try to avoid the Trump China tariffs (which artificially inflated the entire non-oil import total), that’s not a bad performance at all.

The aircraft effect has been much more dramatic this year. Year-to-date through September, the Made in Washington deficit is up from that $630.29 billion to $663.55 billion. Yet the nosedive in the aircraft surplus (all the way from $23.16 billion to just under $3 billion) accounts for nearly 83 percent of that increase.

Want another aircraft effect? Check out the manufacturing trade deficit – so rightly the focus of the President’s attention. Month-to-month, it rose by only 1.46 percent. But the new September level of $103.87 billion is the second-worst monthly total of all time – just behind July’s $104.63 billion. Even worse: The aircraft industry’s problems didn’t add to this number, since its trade deficit actually shrunk slightly on month.

But for the entire year so far, the plunge in the aircraft surplus (which, not so coincidentally, has been mirrored by smaller but not trivial reductions in the surpluses of all sorts of aircraft parts, including engines) has made a sizable difference. From January-September, 2019 to this year’s comparable period, the manufacturing trade shortfall has grown by $10.18 billion, from $777.60 billion to $787.78 billion. Take out the $20.16 billion worsening of the aircraft trade surplus, and the $10.18 billion higher year-to-date manufacturing trade deficit becomes a nearly $10 billion lower year-to-date manufacturing trade deficit.

And when it comes to both the manufacturing and overall Made in Washington trade deficits and a virus effect, don’t forget its healthcare goods component. Specifically, the U.S. trade deficit in pharmaceutical preparations jumped by $12.58 billion year-to-date between last year and this year, and in the categories containing (but not restricted to) protective gear like masks and gowns, testing swabs, ventilators, and oxygen tents by another $2.33 billion.

Since China remains so important for Made in Washington and manufacturing trade flows, bilateral exports, imports, and deficits not surprisingly reveal a major pandemic effect, too. The big China difference is how strongly the September data confirm that President Trump’s goals of reducing the bilateral trade gap and decoupling economically from the People’s Republic are being achieved even without taking the CCP Virus into account.

On a monthly basis, the goods trade gap with China dipped fractionally in September, to $29.67 billion. This total represented the second straight such drop and the lowest level since Aprils $28.40 billion. These merchandise imports inched up sequentially in September by just under one percent and have been virtually flat since July, but goods exports improved by 4.53 percent.

On a year-to-date basis, America’s China trade looks like it’s in even better shape. U.S. goods imports from China are off by nearly 11 percent ($37.54 billion) over this stretch, and the trade gap has become 15.24 percent ($40.06 billion) smaller.

This progress, moreover, has been achieved even though total U.S. exports of civilian aircraft and parts (including engines) to China have shrunk by $4.09 billion and the trade deficit in the virus-related medical equipment categories has risen by $1.25 billion. (Oddly, the bilateral pharmaceutical preparations trade balance has improved with the surplus improving from $449 million to $836 million.)

When all of these virus-related complications and the inevitably disruptive and therefore initial efficiency-reducing impact of the Trump trade policies are considered, two questions arise that are equally fascinating and important. First, once these temporary shocks pass, will this approach to globalization look more like a win or a loss for the U.S. economy? Second, will American election politics give the nation a chance to find out?

Following Up: Inside April’s U.S. Manufacturing Crash II

Tags

aerospace, appliances, automotive, CCP Virus, chemicals, components, computers, coronavirus, COVID 19, durable goods, electrical equipment, electronics, fabricated metals products, Federal Reserve, Following Up, food products, healthcare goods, inflation-adjusted output, machinery, manufacturing, manufacturing output, manufacturing production, medical devices, metals, non-durable goods, paper, real growth, Wuhan virus

A little earlier today, RealityChek presented some lowlights from this morning’s Federal Reserve U.S. manufacturing production report (for April). As promised, here’s a more granular look at the results, which yield even more insights as to how the CCP Virus blow to the economy is reflecting – and probably influencing dramatically changed spending patterns.

The table below shows the findings for durable goods industries, the super-category that covers products with expected usage and shelf lives of three years or more. Included are the original March inflation-adjusted output changes, the revised March data, and the April statistics:

Wood products:                                                -4.22%       -3.15%      -9.04%

non-metallic mineral products:                        -6.56%      -6.50%     -16.26%

Primary metals:                                                -2.82%      -3.95%     -20.37%

Fabricated metal products:                               -8.28%      -4.23%     -11.33%

Machinery:                                                       -5.56%      -3.05%     -10.98%

Computer & electronic products:                     -1.89%      -1.24%      -5.02%

Electrical equip, appliances, components:       -2.24%      -2.83%      -5.99%

Motor vehicles and parts:                               -28.04%    -29.96%    -71.69%

Aerospace/miscellaneous transport equip:      -8.12%      -8.90%     -21.65%

Furniture and related products:                       -9.99%      -6.50%     -20.60%

Miscellaneous manufacturing:                        -9.94%      -7.09%       -9.05%

   (contains most of those non-pharmaceutical healthcare goods)

As in the broader category analysis from earlier today, the automotive collapse – over both March and April – stands out here, although it was joined in the double-digit neighborhood (at much lower absolute levels of course) by six of the other eleven sectors. And as predicted in last month’s post on the March Fed report, the sector that’s held up best has been the computer and electronics industry – though following surprisingly close behind is electrical equipment, appliances, and their components.

It’s also easy to see how the rapid deterioration in automotive and the miscellanous transportation category that includes aerospace (especially in April for the latter) spilled over into supplier industries like metals and fabricated metal products, and machinery.

One durable goods puzzle: the relatively fast April decrease in the miscellaneous manufacturing category, which contains non-pharmaceutical medical goods so crucial for the nation’s CCP Virus response.

The second table shows the same information for the non-durables super-category, where the virus impact has been considerably lighter. Among notable results – the sharp worsening of after-inflation output in the food sector. Although it fared relatively well, there can be little doubt that the worker safety problems in meat-packing plants, along with the cratering of big customers – mainly the restaurant and hotel businesses – played big roles.

The non-durables results also make clear that the sector that’s survived best so far has been paper. Also excelling (at least relatively speaking): the enormous chemicals sector. This industry also contains the pharmaceutical industry, although the any positive CCP Virus impact seems unlikely to date because no vaccines or treatments have been developed yet.

Food, beverage, and tobacco products:          -0.76%      -1.56%       -7.10%

Textiles:                                                        -14.05%      -6.98%     -20.72%

Apparel and leather goods:                          -16.54%    -10.31%     -24.10%

Paper:                                                            -2.04%      -0.08%        -2.58%

Printing and related activities:                    -18.18%    -10.75%      -21.16%

Petroleum and coal products:                       -5.93%      -6.56%      -18.55%

Chemicals:                                                   -1.65%      -1.50%         -5.14%

Plastics and rubber products:                      -7.60%       -4.37%       -11.03%

Other mfg (different from misc above):     -5.37%       -4.29%       -10.37% 

The virus crisis contains so many moving parts (e.g., vaccine and therapeutics progress; infection, fatality, and testing data; uneven state reopening and national social distance practicing; consumer attitudes; second wave possibilities) that extrapolating the manufacturing trends to date seems foolhardy. But tracking industry’s winners and losers as the months pass could still provide important clues as to how much further the economic woes it’s caused will continue; and when, how quickly, and how completely recovery arrives.   

(What’s Left of) Our Economy: New Fed Manufacturing Figures Show No Burst So Far in Anti-CCP Virus Goods Output

Tags

(What' Left of) Our Economy, CCP Virus, coronavirus, COVID 19, facemasks, Fed, Federal Reserve, healthcare goods, industrial production, inflation-adjusted growth, manufacturing, manufacturing output, medical devices, medical equipment, PPE, protective gear, ventilators, Wuhan virus

No one should have been surprised by this morning’s manufacturing output report from the Federal Reserve, which judged that industry’s inflation-adjusted production tumbled by 6.27 percent in March from February’s levels – which was revised downward slightly from a 0.12 percent gain from a 0.02 percent dip. In other words, “Thanks, China!” for the CCP Virus that’s caused an unprecedented shutdown of huge sections of the U.S. economy.

Lately, however, some manufacturing sectors of special concern have emerged – the healthcare goods sectors. And the results are below.

Unfortunately, the statistics in the relevant sectors aren’t very granular. In particular, they don’t enable us to distinguish between, say, masks and ventilators, or between final pharmaceutical products and vaccines, or between CAT-scan and MRI machines and non-medical high tech instruments. Still, the following sequential results must have some significance, given the overall skid in after-inflation manufacturing production. And for February-March, they are:

soaps, cleaning compound, & toilet preparation:      +1.85 percent

pharmaceuticals & medicines:                                  +0.50 percent

  (includes vaccines)

medical equipment & supplies:                                 -1.55 percent

  (includes everything from ventilators to facemasks)

Less helpful is learning that constant dollar output in a category called “navigational, measuring, electromedical and control instruments” decreased by 2.39 percent on month.

Keep in mind that since these data were compiled, all manner of manufacturing companies have volunteered, or been officially pressured, either to ramp up their existing healthcare goods production greatly, or to enter the field. So next month’s Fed industrial production report – for April – should be more revealing. For now, however, the March numbers don’t show much in the way of surge production.

Nor should anyone expect the Fed’s figures on manufacturing capacity and capacity utilization to shed much light on healthcare-related surge performance and surge capacity. The categories simply aren’t this detailed.

Maybe one of the CCP Virus-induced changes in government will be involve tracking healthcare-related manufacturing data in more detailed? Stay tuned. And send all such suggestions to

Jerome Powell, Chair, Board of Governors of the Federal Reserve System, 20th St. and Constitution Ave. NW, Washington, D.C.  20551

 

Making News: On National Radio Tonight on America’s Healthcare Goods Foreign Dependency

Tags

CCP Virus, coronavirus, COVID 19, drugs, health security, Making News, medical devices, pharmaceuticals, PPE, protective gear, The Jim Bohannon Show, Westwood One, Wuhan virus

I’m pleased to announce that I’m slated to appear tonight on “The Jim Bohannon Show” on the nation-wide Westwood One network.  The segment, scheduled to begin at 10 PM EST, will deal with America’s dangerous reliance on imports for vital medicines, medical devices, and protective gear for healthcare workers.

You can listen live on-line at this link to this timely discussion of the nation’s at-risk health security.  And as usual, I’ll post a link to the podcast when it’s available.

Also, keep checking in with RealityChek for news of upcoming media appearances and other developments.

Making News: American Conservative Article Details Scary U.S. Health Security Vulnerability

Tags

CCP Virus, coronavirus, COVID 19, facemasks, health security, imports, Making News, medical devices, pandemics, pharmaceuticals, The American Conservative, Trade, Wuhan virus

I’m pleased to announce the publication of my latest freelance article.  Posted this morning at TheAmericanConservative.com, it presents never-before-seen statistics (gleaned from official U.S. government data) showing alarming U.S. vulnerability to cutoffs of vital medical goods from abroad. P.S.  It makes clear that the problem far transcends China.

And keep checking in at RealityChek for news of media appearances and other developments.

Those Stubborn Facts: Why Health Security Should “Trump” Free Trade for Americans

Tags

active pharmaceutical ingredients, CCP Virus, China, coronavirus, COVID 19, European Union, exports, free trade, globalization, health security, India, medical devices, pandemic, pharmaceuticals, surgical equipment, Those Stubborn Facts, Trade

“[White House Office of Manufacturing and Trade Policy Director Peter] Navarro raised a lot of eyebrows when he warned that [international trade] fights over [healthcare-related goods] loomed and told Fox Business Network on Feb. 23: ‘People need to understand in crises like this, we have no allies.’ But what then seemed potentially alarmist now looks like foresight.”

– Bloomberg News, March 16, 2020

Number of countries that have curbed exports of healthcare-related goods*: 38**

 

*Includes pharmaceuticals, active pharmaceutical ingredients, medical devices, surgical appliances and supplies

**India, China, India, Taiwan, Indonesia, Belarus, Malaysia, Thailand, South Korea, Russia, United Kingdom, and the 27 members of the European Union

 

(Sources: “Export Wars Erupt as Officials Curb Supplies to Battle Virus,” by Shawn Donnan, Bloomberg News, March 16, 2020, https://www.bloomberg.com/news/articles/2020-03-16/trade-war-latest-welcome-to-the-coronavirus-export-wars-of-2020-k7uf1k01; “The Global Mask Shortage May Get Much Worse,” by K Oanh Ha, Ibid., March 10, 2020, https://www.bloomberg.com/news/articles/2020-03-10/the-global-mask-shortage-may-be-about-to-get-much-worse; “Export Trade News,” Foreign Trade Online [latest daily edition], https://www.foreign-trade.com/export_trade.htm; “The World Needs Masks. China Makes Them – But Has Been Hoarding Them,” by Keith Bradsher and Liz Alderman, The New York Times, March 16, 2020, https://www.nytimes.com/2020/03/13/business/masks-china-coronavirus.html; and “UK bans parallel export of two COVID-19 treatment candidates to protect national supply,” by Janet Beal, “Life Sciences,” IHS Markit, February 26, 2020, https://ihsmarkit.com/research-analysis/uk-bans-parallel-export-of-two-covid19-treatment-candidates.html)

Making News: Back on National Radio Tonight Talking China, the U.S., & the Wuhan Virus…& More!

Tags

Breitbart News Tonight, China, conservatives, coronavirus, COVID 19, globalization, Gordon G. Chang, health security, Making News, manufacturing, medical devices, offshoring, pandemics, pharmaceuticals, Republicans, The Epoch Times, The John Batchelor Show, Wuhan virus

I’m pleased to announce that I’m scheduled to return to John Batchelor’s nationally syndicated radio show tonight to talk about U.S.-China relations “in a time of Wuhan Virus.”  (Spoiler alert:  They’re not good.  And barring a sea change in China’s behavior, they shouldn’t be.)

The segment, which will also feature co-host Gordon G. Chang, is slated to start at 10:15 PM EST and you can listen live here.  Can’t tune in tonight?  I’ll be posting a link to the podcast as soon as one’s available.

Speaking of podcasts, here’s one of a “Breitbart News Tonight” interview from last Friday night on the economics and politics of this coronavirus era, with a special focus on the implications for small-government Republicans and conservatives.  Click here and scroll down till you see my name.  Moreover, if you’re not into podcasts, you can read a fine summary at this link.  FYI, I don’t use the phrase “extinction event” often.

Finally, my views were covered recently in two Epoch Times articles.  In the first, from March 3, I emphasized the importance of trade and related economic policies needed to ensure that the United States regains its ability to supply its own pharmaceutical and medical device needs.  In the second, I similarly observed that the very idea of globalizing and offshoring the domestic manufacturing base has become more urgent than ever to challenge given emerging threats like pandemics.

And keep checking in with RealityChek for news of upcoming media appearances and other developments.

(What’s Left of) Our Economy: When Washington Slept on America’s Dangerous Dependency on Foreign Healthcare Products

Tags

active pharmaceutical ingredients, Bureau of Industry and Security, China, China virus, Commerce Department, coronavirus, COVID 19, globalization, health security, healthcare, India, medical devices, national security, Office of Technology Evaluation, offshoring, pharmaceuticals, supply chains, surgical equipment, Trade, {What's Left of) Our Economy

Last week I wrote that no one in American politics, in either party, deserves blame for failing to anticipate the China Virus outbreak (in the sense of being ready for a genuine pandemic), and especially the Trump administration’s flawed response to its spread within the United States (as opposed to its timely decision on January 31 to start curbing inbound travel from overseas – initially from China). 

But there’s one big aspect of coronavirus-related public policy where potentially calamitous and avoidable mistakes have been made, and where identifying responsibility is essential (largely to prevent repetition). That’s the growth of America’s dependence on pharmaceuticals, their active ingredients, and other healthcare-related goods from foreign sources, especially from China.

It should have been obvious long before the virus broke out in Wuhan (at least as far as we know) that health security is national security, and that the blithe approval of trade and related policies that encouraged the offshoring of production in this crucial sector was as dangerous as the offshoring of crucial defense and defense-related (because so many inputs to weapons and platforms aren’t weapons themselves) products. Even louder alarm bells should have sounded once it became clear that a leading offshoring destination was China – a dictatorship that has challenged U.S. national security interests long before the rise of current leader Xi Jinping, and whose role in medical supply chains inevitably created the threat of supply cutoffs (as has recently been threatened in the Chinese government-controlled press).

And indeed American policymakers had all the evidence they needed as early as 2011. That’s when a small office at the Commerce Department called the Bureau of Industry and Security (BIS) issued a report called – yup – “Reliance on Foreign Sourcing in the Healthcare and Pubic Health (HPH) Sector: Pharmaceuticals, Medical Devices, and Surgical Equipment.”

For many years, BIS’ Office of Technology Evaluation (OTE) has been issuing reports on sectors of the U.S. defense industry and other portions of the economy critical to the nation’s security and their use of foreign parts, components, materials, and other inputs whose availability shouldn’t be taken for granted. And fortunately, the Office and the various acts of Congress that have defined its mission have long understood that, as suggested above, national security-related industries are by no means restricted to those that turn out products that go bang and boom.

Notably, the study was requested by the Obama administration’s Department of Homeland Security (DHS), which shows commendable foresight. And the main results make jaw-dropping reading today:

>“There is a significant amount of U.S.-based manufacturing for critical healthcare-related commodities.” At the same time, “There is…a very high degree of foreign sourcing and dependency for components, materials, and finished products.”

>“Exposure to supply disruptions is widespread, but many respondents consider it a cost of doing business in the healthcare industry.”

>As a result, “Only 34 percent of respondents are taking steps to reduce their exposure to foreign sourcing and dependency issues.”

>When it comes to the chemical ingredients for drugs, where heavy China dependency has attracted so much attention today, in 2011, pharmaceutical companies reported “difficulty limiting their exposure to foreign dependencies primarily because most of the APIs [active pharmaceutical ingredients] are produced outside the United States.”

>Medical device producers stated that they were “vulnerable primarily due to their reliance on other countries for electronic parts.” Japan was the main concern, due at least in part to the earthquake that year that disrupted many industries’ supply chains. But China has become an even more important supplier since then.

Sadly, however, the record also demonstrates that once the findings came in, no serious follow-through was undertaken.

OTE surveyed 161 companies – 70 pharmaceutical producers, 75 manufacturers of medical devices and surgical equipment, and 16 companies that turned out both kinds of products. Roughly three fourths of these companies were headquartered in the United States and roughly one-fourth were foreign owned.

All told, these firms produced 868 individual pharmaceuticals and 833 kinds of medical devices or surgical equipment. Of these, in turn, 290 pharmaceuticals and 128 types of devices and equipment were deemed by OTE “critical to effective healthcare services in the United States,” meaning “needed in various emergency scenarios.” The bureau also looked into the chemical ingredients and parts and components comprising these products.

As for the specific information sought, here it is:

“Survey respondents were asked to identify the pharmaceuticals and medical devices/surgical equipment they manufactured, integrated/assembled, and/or sold for use in the United States. For each product area selected, companies were then asked to provide the top three company proprietary products they make and the location of manufacture. Finally, companies identified, to the best of their knowledge, whether they were the sole U.S.-based manufacturer, sole global manufacturer, or not the sole manufacturer of each product.”

Some of the above results in greater detail:

More than 73 percent of the total surveyed companies depended on suppliers located abroad for at least one critical component, manufacturing material, or actual finished good. And the average number of such foreign-sourced goods per company surveyed was 11.4. Seventy-nine percent of pharmaceutical firms surveyed reported themselves in this situation versus 63.7 percent of the device and equipment manufacturers, and the average number of foreign-sourced products was 11.4 for the drug companies versus 9.8 for their device and equipment manufacturers.

Interestingly, even at this point, China loomed pretty large large in the picture at that time – especially for medical devices and surgical equipment. Its entities represented 13.8 percent of the total number of foreign suppliers to U.S.-based producers. For pharmaceutical companies, they accounted for 9.1 percent – less than leader Italy (15.7 percent), India (12.8 percent), and Germany (10.6 percent). Not that this result should be especially comforting, as India – a major global producer of generic drugs – has recently announced to restrict exports because it’s experiencing difficulty getting chemicals from China and (surprise?) wants to make sure it can provide for its own population.

The OTE survey, in other words, found that, in 2011, healthcare products companies operating in the United States relied on a diverse global supply chain. But significant vulnerabilities were reported, too. Principally, for pharmaceuticals, “there was no U.S.-based source for at least 65.5 percent of [total goods] identified by survey respondents.” And for medical devices and surgical equipment, the figure was at least 60.5 percent. More troublingly, in the device and equipment sectors, the greatest dependencies tended to be in complex products.

Moreover, when thinking about the safety of imported healthcare goods, keep in mind BIS’ finding that only 60.3 percent of the companies in total could identify the suppliers of their suppliers.

Nor were significant supply disruptions unknown by healthcare products companies. Thirty percent of these businesses reported experiencing at least one of these events between 2007 and 2010, 40 percent of these came from foreign suppliers, and 17.5 percent came from China – the biggest share for any single country. Both domestic- and foreign-origin disruptions lasted an average of 155 days. Nonetheless, these figures are surely way too low, as only 18.3 percent of responding companies said they tracked foreign supply disruptions.

Even so, the study oddly found that “Only 16.6 percent of companies foresee a risk of supply disruptions from outside of the United States” but that 29 percent “believed their company was vulnerable to serious and/or prolonged supply chain disruptions from events or dependencies outside the United States.” For pharmaceuticals, the top concern again was lack of API availability domestically.”

OTE made several policy recommendations to strengthen America’s health security. For example, various major relevant federal agencies should “further examine [the] survey data to prioritize the foreign sourcing and dependencies that could have the greatest impact on the healthcare supply chain in an emergency situation.”

In addition, these agencies, “in coordination with DHS and the Department of Commerce, should assess whether the use of Defense Production Act authorities, such as the Defense Priorities and Allocations System (DPAS), could provide the ability to rapidly expand or surge capacity of U.S.-based pharmaceutical and medical device/surgical equipment facilities to meet demand in an emergency situation.” As made clear, however, by the continued sky-high levels of the healthcare industry’s China and other foreign dependencies, the problem was promptly ignored.  

Such measures, along with many others in the trade, tax, and regulatory fields will no doubt be crucial to rebuilding the kind of domestic healthcare industry so many Americans and even their leaders finally recognize is essential. But if the nation really is seriously behind the idea that health security is national security, it’s going to need updated detailed information on foreign dependencies. In other words, time to put the OTE to work again.